Orimed Pharma

orimedpharma.ca

Orimed is an up and coming, innovative Canadian pharmaceutical company, actively involved in the fields of sexual dysfunctions for women and men, bone health, pain and insomnia with new therapeutic fields on the horizon.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

MATRIC TO ESTABLISH FIRST AND ONLY NATIONAL CENTER OF EXCELLENCE FOR PHARMACEUTICAL PROCESS DESIGN

The Mid-Atlantic Technology, | March 03, 2022

news image

The Mid-Atlantic Technology, Research & Innovation Center announced it will establish the Center of Excellence for process design, defining a new standardized process development framework to streamline chemical manufacturing processes from laboratory bench through to commercial production. The initial projects will develop continuous processes for critical materials for the pharmaceutical industry currently substantially produced overseas. These new capabilities will be established as a res...

Read More

Business Insights

NEXTRNA LAUNCHES WITH $56 MILLION IN FUNDING TO BRING TRANSFORMATIVE NON-CODING RNA-DIRECTED MEDICINES TO PATIENTS

NextRNA Therapeutics | March 02, 2022

news image

NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop transformative therapeutics, announces its launch with $9.3 million in seed financing and a $46.8 million Series A led by Cobro Ventures and Lightchain Capital, with additional participation from Circle Alternative Investments, Evans Capital, Jefferies, Rivas Capital, and Willett Advisors. Proceeds will be used by the company to augment its target and drug discovery engine, expand its pipeline, an...

Read More

PREMIER INC. SUPPORTS FDA, DEA REFORMS AND REGULATORY WAIVERS TO COUNTER DRUG SHORTAGES

Premier Inc. | July 24, 2020

news image

Premier Inc. today provided the U.S. Food and Drug Administration (FDA) and the U.S. Drug Enforcement Administration (DEA) with a list of reforms and regulatory waivers that the company believes should be extended beyond the COVID-19 pandemic and made permanent thereafter in order to prevent drug shortages. “During the height of the COVID-19 pandemic, we saw demand for many common pharmaceuticals surge by an average of more than 150 percent,” said Blair Childs, Premier...

Read More

Pharma Tech

CALYX NAMED MEDICAL IMAGING PROVIDER BY CLINSCIENCE

Calyx | June 10, 2022

news image

Calyx, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research, announced it has been named an approved provider of centralized medical imaging services by Clinscience, a full service CRO offering smart, end-to-end clinical trial services to the global pharmaceutical industry. "Calyx's commitment to reliably solving the complex aligns with our focus on designing integrated, smart...

Read More
news image

Business Insights

MATRIC TO ESTABLISH FIRST AND ONLY NATIONAL CENTER OF EXCELLENCE FOR PHARMACEUTICAL PROCESS DESIGN

The Mid-Atlantic Technology, | March 03, 2022

The Mid-Atlantic Technology, Research & Innovation Center announced it will establish the Center of Excellence for process design, defining a new standardized process development framework to streamline chemical manufacturing processes from laboratory bench through to commercial production. The initial projects will develop continuous processes for critical materials for the pharmaceutical industry currently substantially produced overseas. These new capabilities will be established as a res...

Read More
news image

Business Insights

NEXTRNA LAUNCHES WITH $56 MILLION IN FUNDING TO BRING TRANSFORMATIVE NON-CODING RNA-DIRECTED MEDICINES TO PATIENTS

NextRNA Therapeutics | March 02, 2022

NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop transformative therapeutics, announces its launch with $9.3 million in seed financing and a $46.8 million Series A led by Cobro Ventures and Lightchain Capital, with additional participation from Circle Alternative Investments, Evans Capital, Jefferies, Rivas Capital, and Willett Advisors. Proceeds will be used by the company to augment its target and drug discovery engine, expand its pipeline, an...

Read More
news image

PREMIER INC. SUPPORTS FDA, DEA REFORMS AND REGULATORY WAIVERS TO COUNTER DRUG SHORTAGES

Premier Inc. | July 24, 2020

Premier Inc. today provided the U.S. Food and Drug Administration (FDA) and the U.S. Drug Enforcement Administration (DEA) with a list of reforms and regulatory waivers that the company believes should be extended beyond the COVID-19 pandemic and made permanent thereafter in order to prevent drug shortages. “During the height of the COVID-19 pandemic, we saw demand for many common pharmaceuticals surge by an average of more than 150 percent,” said Blair Childs, Premier...

Read More
news image

Pharma Tech

CALYX NAMED MEDICAL IMAGING PROVIDER BY CLINSCIENCE

Calyx | June 10, 2022

Calyx, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research, announced it has been named an approved provider of centralized medical imaging services by Clinscience, a full service CRO offering smart, end-to-end clinical trial services to the global pharmaceutical industry. "Calyx's commitment to reliably solving the complex aligns with our focus on designing integrated, smart...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us